1. Scrip
  2. >>R&D

Padcev Positioned For Urothelial Cancer Expansion

US sBLA Planned Soon

 
• By Ian Haydock

First-in-class ADC set for expanded use on the back of additional data, but analysts see first-line setting as probably the main growth driver.

urothelial cancer
Padcev Moving Ahead In Urothelial Cancer Settings • Source: Shutterstock

Seagen Inc. and partner Astellas Pharma, Inc. have presented additional clinical results for Padcev (enfortumab vedotin) confirming significant improvements in both overall and progression-free survival versus chemotherapy in previously treated urothelial cancer patients, and setting up the first-in-class antibody-drug conjugate (ADC) for further approval progress in this setting.

Primary results from the global, 600-patient Phase III EV-301 trial were presented at the virtual American Society of Clinical Oncology...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.